Drug Profile


Alternative Names: DDATHF; LY 264618; T 904064; T-64

Latest Information Update: 02 Dec 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dana-Farber Cancer Institute
  • Class 2 ring heterocyclic compounds; Amides; Glutamates; Pyrimidines
  • Mechanism of Action DNA synthesis inhibitors; Phosphoribosylglycinamide formyltransferase inhibitors; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Sarcoma; Solid tumours

Most Recent Events

  • 31 Jan 2003 Tularik has terminated its licensing agreement for T 64
  • 19 Jun 2002 Discontinued - Phase-II for Breast cancer in Australia (IV)
  • 19 Jun 2002 Discontinued - Phase-II for Breast cancer in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top